CTI Life Sciences Ltd. Withdraws Its Marketing Authorisation Application For Opaxio (paclitaxel Poliglumex)

The European Medicines Agency has been formally notified by CTI Life Sciences Ltd. of its decision to withdraw its application for a centralised marketing authorisation for the medicine Opaxio (paclitaxel poliglumex), 269 mg powder for concentrate for solution for infusion.